Robot
21.Mar.25 1:18 AM

Neutral Rating from Goldman Sachs Amidst Mixed Outlook

Goldman Sachs analyst Noah Poponak initiated coverage on Amentum Holdings, Inc. (AMTM) with a Neutral Rating and a price target of $21, citing the company's lower relative valuation compared to peers and opportunities for growth from its merger with Jacobs' government services business. However, Poponak also noted challenges such as slower growth, lower margins, and sector headwinds, leading to a mixed outlook for Amentum.
Robot
21.Mar.25 1:03 AM

Quantum Computing Inc. Reports Q4 Loss, Shares Slide in After-Hours Trading

Quantum Computing Inc. (QUBT) shares fell in Thursday's after-hours session after the company reported a wider-than-expected loss for the fourth quarter. Despite the loss, the company remains optimistic about its future, citing a strong financial position and progress on its Quantum Photonic Chip Foundry.
Robot
21.Mar.25 12:55 AM

Beat on Revenue, Miss on Expectations, Stock Price Falls 4.18%

Lennar Corporation reported first-quarter earnings of $2.14 per share, exceeding analyst expectations of $1.73, but its stock price fell 4.18% in after-hours trading due to lower-than-expected average sales prices and margins. Despite the decline, the company remains optimistic about its future prospects and continues to focus on its strategic goals.
Robot
21.Mar.25 12:49 AM

Elon Musk and Ted Cruz Discuss Marijuana on Podcast, Musk Jokes About 4/20 Birthday

Elon Musk and Senator Ted Cruz discussed the possibility of smoking marijuana on Cruz's podcast, "Verdict with Ted Cruz," with Musk playfully referencing his birthday being 69 days after 4/20, the cannabis holiday. Musk, who now supports mandatory drug testing for federal employees, previously faced backlash and consequences for smoking marijuana on Joe Rogan's podcast in 2018.
Robot
21.Mar.25 12:36 AM

Early Advantage in a Growing Weight-Loss Market, But Competition Looms

Eli Lilly's weight-loss drug Mounjaro is now available in India at a lower price compared to the US, giving the company an early advantage in the growing market. Despite facing competition from Indian pharmaceutical companies developing generic versions, Lilly's strategic move could significantly contribute to its future growth.